Updated:
Icahn School of Medicine at Mount Sinai (MSSM)
The Icahn School of Medicine at Mount Sinai was established in 1963 and renamed in 2012 following Carl Icahn's gift. It operates under the Mount Sinai Health...
Icahn School of Medicine at Mount Sinai (MSSM)
The Icahn School of Medicine at Mount Sinai was established in 1963 and renamed in 2012 following Carl Icahn's gift. It operates under the Mount Sinai Health System with Kenneth L. Davis as CEO of the parent entity. The endowment targets venture and growth investments in biotechnology and healthcare. Confirmed holdings include positions in Linus Biotechnology, Click Therapeutics, CastleVax, Allergenis, Amathus Therapeutics, Verici Dx and Kantaro Biosciences. All activity occurs through Mount Sinai Innovation Partners. Geographic focus centers on the United States with primary operations in New York. The school maintains 4,560 professionals and holds direct real estate assets including the Icahn Medical Institute Building and Annenberg Building. Adjacent vehicles include the Black Family Stem Cell Institute, Friedman Brain Institute and Mount Sinai Health Care Foundation. No operational events from the last 24 months appear in available records. The endowment's structure routes investments exclusively through Mount Sinai Innovation Partners, creating a dedicated vehicle for commercializing faculty research separate from the core academic mission.
General information
Firm type
Endowment / Foundation
Year founded
1963
Location
Region
North America
Country
United States
City
New York
Corporate office
1 Gustave L. Levy Place, New York, NY 10029-5674, United States
Principals
Dennis S. Charney
Dean
Altss tracks 2 additional named team members for this firm — including direct investment leads, IR, and operating principals not listed on the public website.
Book a demoSector focus
Frequently asked questions
Who runs investment decisions at Icahn School of Medicine at Mount Sinai?
Dennis S. Charney serves as dean. Mount Sinai Innovation Partners handles commercialization and investment activity with Erik Lium as a listed contact.
Does Icahn School of Medicine at Mount Sinai participate in fund commitments or only direct deals?
Activity centers on direct ownership in startups through Mount Sinai Innovation Partners. No fund commitments are disclosed.
What investment stages does Icahn School of Medicine at Mount Sinai typically target?
The endowment focuses on early stage and startup investments in biotechnology and healthcare.
Where does the underlying wealth come from?
The endowment originates from institutional and philanthropic sources including a $200 million gift from Carl Icahn in 2012.
How is Icahn School of Medicine at Mount Sinai related to Mount Sinai Health System?
The school serves as the academic teaching arm with Mount Sinai Health System as its parent entity and sole member.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: